Globeimmune, Inc. (OTCMKTS:GBIM – Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0001. Globeimmune shares last traded at $0.00, with a volume of 44,281 shares.
Globeimmune Stock Down 100.0%
About Globeimmune
GlobeImmune, Inc, a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.
Further Reading
- Five stocks we like better than Globeimmune
- The Risks of Owning Bonds
- Amazon Is One of the Clearest Buys If the Market Dips Again
- Investing In Preferred Stock vs. Common Stock
- CoreWeave’s Guidance Cut: A Buying Opportunity in Disguise?
- 3 Dividend Kings To Consider
- Strategy Shares Plunge as Bitcoin Retreats—More Pain Ahead?
Receive News & Ratings for Globeimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globeimmune and related companies with MarketBeat.com's FREE daily email newsletter.
